Immunomodulatory drugs and intravenous immunoglobulin (IVIg) for patients with chronic demyelinating polyneuropathy who are in remission a review of clinical and cost-effectiveness and guidelines
The purpose of this rapid review is therefore to compare the available evidence on immunomodulatory drugs, alone or in combination with a lower concentration of intravenous immunoglobulin (IVIg), in terms of their comparative clinical effectiveness, safety and cost-effectiveness for patients with ch...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
[Ottawa]
Canadian Agency for Drugs and Technologies in Health
13 Mar 2015, 2015
|
| Series: | Rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this rapid review is therefore to compare the available evidence on immunomodulatory drugs, alone or in combination with a lower concentration of intravenous immunoglobulin (IVIg), in terms of their comparative clinical effectiveness, safety and cost-effectiveness for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) under remission. Furthermore, guidelines on maintenance therapy for CIDP patients in periods of remission were identified and assessed |
|---|---|
| Physical Description: | 1 PDF file (12 pages) illustration |